Abstract
Infants are the most vulnerable population at risk for serious diseases. Respiratory syncytial virus (RSV) is a disease that can be detrimental in infants because of their immature lungs and immune system. Palivizumab, a humanized monoclonal antibody medication, given every 28-30 days has been shown to reduces RSV symptoms and decrease rates of hospitalization by 15%. By reducing the rate of hospital stay, it will also reduce cost.
Date of publication
Spring 4-29-2020
Document Type
MSN Capstone Project
Language
english
Persistent identifier
http://hdl.handle.net/10950/2629
Degree
MSN in Education
Recommended Citation
Hang, William, "Decreasing Hospitalization in Infants" (2020). MSN Capstone Projects. Paper 32.
http://hdl.handle.net/10950/2629
Included in
Family Practice Nursing Commons, Maternal, Child Health and Neonatal Nursing Commons, Pediatric Nursing Commons